Abstract
Background Infection with herpes simplex virus type 2 (HSV-2) is common worldwide and an important risk factor for HIV infection. Aetiological diagnosis of HSV-2 is typically determined with the use of commercially available type-specific enzyme-linked immunosorbent assays (ELISAs). This study aimed to determine the prevalence of HSV-2 among people attending sexual health clinics in the Highlands of Papua New Guinea. The study also aimed to compare the performance of two type-specific ELISA assays, the Kalon and HerpeSelect glycoprotein G2 assays, in this context. Methods: Participants were recruited as part of a longitudinal sexual health study. Participants attended four appointments over a 12-month period and had blood taken for HSV-2 serology at each time point. Both the Kalon and HerpeSelect assays were performed as per manufacturer's instructions. Results: A total of 132 participants were tested for HSV-2 using the Kalon and HerpeSelect ELISAs. HSV-2 prevalence was 52% (95% CI, 43-60) and 61% (95% CI, 52-69) with Kalon and HerpeSelect assays respectively. There was high concordance (87%, ?≤0.75, P<0.001, n≤115) between the two assays at the manufacturer recommended index value cut-offs. For participants with discordant results at baseline, (n≤16), three sero-conversions were observed over the 12-month period when sequential sera was tested. Conclusions: A high HSV-2 prevalence was observed in this clinic-based population. Our longitudinal data indicate the higher prevalence of HSV-2 detected with the HerpeSelect ELISA was likely due to false positives rather than a higher sensitivity in the early stages of infection.
| Original language | English |
|---|---|
| Pages (from-to) | 575-579 |
| Number of pages | 5 |
| Journal | Sexual Health |
| Volume | 11 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 1 Dec 2014 |
| Externally published | Yes |
Cite this
}
Comparative performance of the Kalon and HerpeSelect enzyme-linked immunosorbant assays to determine the prevalence of herpes simplex virus type 2 in Papua New Guinea. / Ryan, Claire E.; Simbiken, Cassey S.; Agius, Paul A.; Allen, Joyce; Sauk, Joyce; Kaima, Petronia; Kombati, Zure; Siba, Peter; Kaldor, John M.; Vallely, Andrew; Male Circumcision Acceptability Team; Impact Study MCAIS Team.
In: Sexual Health, Vol. 11, No. 6, 01.12.2014, p. 575-579.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Comparative performance of the Kalon and HerpeSelect enzyme-linked immunosorbant assays to determine the prevalence of herpes simplex virus type 2 in Papua New Guinea
AU - Ryan, Claire E.
AU - Simbiken, Cassey S.
AU - Agius, Paul A.
AU - Allen, Joyce
AU - Sauk, Joyce
AU - Kaima, Petronia
AU - Kombati, Zure
AU - Siba, Peter
AU - Kaldor, John M.
AU - Vallely, Andrew
AU - Male Circumcision Acceptability Team
AU - Impact Study MCAIS Team
PY - 2014/12/1
Y1 - 2014/12/1
N2 - Background Infection with herpes simplex virus type 2 (HSV-2) is common worldwide and an important risk factor for HIV infection. Aetiological diagnosis of HSV-2 is typically determined with the use of commercially available type-specific enzyme-linked immunosorbent assays (ELISAs). This study aimed to determine the prevalence of HSV-2 among people attending sexual health clinics in the Highlands of Papua New Guinea. The study also aimed to compare the performance of two type-specific ELISA assays, the Kalon and HerpeSelect glycoprotein G2 assays, in this context. Methods: Participants were recruited as part of a longitudinal sexual health study. Participants attended four appointments over a 12-month period and had blood taken for HSV-2 serology at each time point. Both the Kalon and HerpeSelect assays were performed as per manufacturer's instructions. Results: A total of 132 participants were tested for HSV-2 using the Kalon and HerpeSelect ELISAs. HSV-2 prevalence was 52% (95% CI, 43-60) and 61% (95% CI, 52-69) with Kalon and HerpeSelect assays respectively. There was high concordance (87%, ?≤0.75, P<0.001, n≤115) between the two assays at the manufacturer recommended index value cut-offs. For participants with discordant results at baseline, (n≤16), three sero-conversions were observed over the 12-month period when sequential sera was tested. Conclusions: A high HSV-2 prevalence was observed in this clinic-based population. Our longitudinal data indicate the higher prevalence of HSV-2 detected with the HerpeSelect ELISA was likely due to false positives rather than a higher sensitivity in the early stages of infection.
AB - Background Infection with herpes simplex virus type 2 (HSV-2) is common worldwide and an important risk factor for HIV infection. Aetiological diagnosis of HSV-2 is typically determined with the use of commercially available type-specific enzyme-linked immunosorbent assays (ELISAs). This study aimed to determine the prevalence of HSV-2 among people attending sexual health clinics in the Highlands of Papua New Guinea. The study also aimed to compare the performance of two type-specific ELISA assays, the Kalon and HerpeSelect glycoprotein G2 assays, in this context. Methods: Participants were recruited as part of a longitudinal sexual health study. Participants attended four appointments over a 12-month period and had blood taken for HSV-2 serology at each time point. Both the Kalon and HerpeSelect assays were performed as per manufacturer's instructions. Results: A total of 132 participants were tested for HSV-2 using the Kalon and HerpeSelect ELISAs. HSV-2 prevalence was 52% (95% CI, 43-60) and 61% (95% CI, 52-69) with Kalon and HerpeSelect assays respectively. There was high concordance (87%, ?≤0.75, P<0.001, n≤115) between the two assays at the manufacturer recommended index value cut-offs. For participants with discordant results at baseline, (n≤16), three sero-conversions were observed over the 12-month period when sequential sera was tested. Conclusions: A high HSV-2 prevalence was observed in this clinic-based population. Our longitudinal data indicate the higher prevalence of HSV-2 detected with the HerpeSelect ELISA was likely due to false positives rather than a higher sensitivity in the early stages of infection.
UR - http://www.scopus.com/inward/record.url?scp=84914159031&partnerID=8YFLogxK
U2 - 10.1071/SH14055
DO - 10.1071/SH14055
M3 - Article
VL - 11
SP - 575
EP - 579
JO - Sexual Health
JF - Sexual Health
SN - 1448-5028
IS - 6
ER -